摘要
目的探讨厄贝沙坦与依那普利治疗中重度高血压的安全性及效果。方法随机选取2013年10月至2015年6月本院收治的中重度高血压患者104例，采用随机数字表法将其平均分为观察A组和观察B组。观察A组氢氯噻嚷联合依那普利治疗，观察B组氢氯噻嚷联合厄贝沙坦治疗。观察记录两组治疗期间血压控制情况及不良反应发生情况。结果观察A组与观察B组治疗后舒张压和收缩压分别为（92．1±7．9）mmHg（1mmHg=0．133kPa）、（90．2±8．3）mmHg和（140．5±15．1）mmHg、（137．9±14．2）mmHg），治疗前分别为（110．3±9．7）mmHg、（111．4±9．9）mmHg和（180．5±15．2）mmHg、（182．1±15．7）mmHg，差异均有统计学意义（P〈0．05），但两组血压、治疗总有效率（92．31％ VS．94．23％）组间比较，差异无统计学意义（P〉0．05）。结论厄贝沙坦或依那普利联合氢氧噻嚷均可有效降低中重度高血压患者血压，对机体代谢影响较小，是2种合理的高血压治疗方案。
Objectives To investigate the clinical efficacy and safety of enalapril and irbesartan in the treatment of patients with moderate or severe hypertension. Methods 104 patients with moderate or severe hypertension admitted into our hospital from October, 2013 to June, 2015 were randomly selected .and were divided into group A and group B according to random number table, 52 for each group. Group A were treated with hydrochlorothiazide and enalapril and group B hydrochlorothiazide and irbesartan. The blood pressure control and adverse reactions of both groups during the treatment were observed and recorded. Results The diastolic blood pressures were （92. 1±7.9）mmHg and （90.2±8.3） mmHg and the systolic blood pressures were （140.5±15.1）mmHg and （137.9±14.2） mmHg after the treatment in group A and group B, respectively.which were significantly lower than those before the treatment [diastolic blood pressures： （110.3±9.7） mmHg and （111.4±9.9） mmHg; systolic blood pressures： （180.5±15.2） mmHg and （182.1±15.7） mmHg], with statistical differences （P〈0.05）. There were no statistical differences in blood pressures and total effective rate （92.31% vs. 94.23%） between these two groups. Conclusions Irbesartan or enalapril combined with hydrochlorothiazide both can effectively decrease the blood pressures in patients with moderate or severe hypertension, has little effect on metabolism, and are reasonable treatment plan.
出处
《国际医药卫生导报》
2016年第10期1420-1422,共3页
International Medicine and Health Guidance News
关键词
高血压
氢氧噻嚷
依那普利
厄贝沙坦
疗效评估
Hypertension
Hydrochlorothiazide
Enalapril
Irbesartan
Efficacy evaluation
